Matthew Vincent Dolan - 28 Jan 2025 Form 4 Insider Report for DEXCOM INC (DXCM)

Signature
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Matthew Vincent Dolan
Issuer symbol
DXCM
Transactions as of
28 Jan 2025
Net transactions value
-$102,820
Form type
4
Filing time
30 Jan 2025, 18:44:26 UTC
Previous filing
16 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Award $0 +3,048 +7.6% $0.000000 43,227 28 Jan 2025 Direct F1, F2
transaction DXCM Common Stock Sale $102,820 -1,183 -2.7% $86.91 42,044 29 Jan 2025 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025.
F2 Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025, and 104 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on August 30, 2024.
F3 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.